News | September 07, 2008

Study Shows Cost Efficiency of Contrast Echocardiography to Triage ED Patients

September 8, 2008 - Excluding cardiac causes in patients presenting to the emergency department (ED) with chest pain using myocardial contrast echocardiography (MCE) can prevent unnecessary admissions, making it a cost-efficient tool in the evaluation of these patients, according to a study published in the Sept. 15 issue of the American Journal of Cardiology.

Assessment of patients presenting to the ED with suspected cardiac chest pain and a nondiagnostic electrocardiogram (ECG) is lengthy and costly and the study’s authors hypothesized MCE could be used as a more cost-efficient way to detecting those with chest pain that is noncardiac in nature. Accordingly, cost-efficiency was evaluated in 957 patients presenting to the ED with suspected cardiac chest pain, but no ST-segment elevation on the ECG, who underwent MCE. Economic outcome calculations were based on costs estimated from national average Medicare charges adjusted by a cost–charge ratio.

Based on routine clinical criteria, 641 patients (67 percent) were admitted to the hospital, whereas 316 (33 percent) were discharged directly from the ED. The average cost per patient using routine evaluation was $5,000. Patients with normal MCE results (523) had a very low primary event rate (death, acute myocardial infarction) of 0.6 percent within 24 hours after presentation, making it relatively safe to discharge patients directly from the ED with a normal MCE result. Researchers said if MCE had been used for decision making, 523 patients (55 percent) would have been discharged directly from the ED and 434 (45 percent) would have been admitted to the hospital, which would have prevented unnecessary admissions and tests and could have saved an average of $900 per patient.

The study was conducted by the Cardiovascular Division and Department of Emergency Medicine, Oregon Health and Science University, in Portland, OR. The work was supported by a grant from GE Healthcare and grants from the National Institutes of Health and the American Society of Echocardiography.

The study was conducted by doctors Jared J. Wyrick, Saul Kalvaitis, K. John McConnell, Diana Rinkevich, Sanjiv Kaul, and Kevin Wei.

For more information: www.ajconline.org

Related Content

Bay Labs Announces New Echocardiography Guidance Software Data at ASE 2019 Scientific Sessions
News | Cardiovascular Ultrasound | June 20, 2019
Bay Labs announced that new data on the company’s first-of-its-kind deep learning investigational guidance software...
LVivo EF Comparable to MRI, Contrast Echo in Assessing Ejection Fraction
News | Cardiovascular Ultrasound | June 19, 2019
DiA Imaging Analysis announced the presentation of two studies assessing the performance and accuracy of the company's...
New Data Demonstrates Safety Profile of GammaTile Therapy for Various Brain Tumors
News | Brachytherapy Systems | June 18, 2019
GT Medical Technologies Inc. announced the presentation of clinical data from a prospective study of GammaTile Therapy...
Black Men Less Likely to Adopt Active Surveillance for Low-Risk Prostate Cancer
News | Prostate Cancer | June 17, 2019
A new study reveals black men are less likely than white men to adopt an active surveillance strategy for their...
AI Biomarker Demonstrates High Predictive Power for Lung Cancer Immunotherapy
News | Artificial Intelligence | May 31, 2019
Lunit announced an abstract presentation of its artificial intelligence (AI) precision medicine research portfolio at...
Dynamic Digital Radiography Used to Assess Undifferentiated Dyspnea
News | Digital Radiography (DR) | May 29, 2019
A clinical study presented at the American Thoracic Society (ATS) 2019 annual meeting, May 17-22 in Dallas, described...
Leica Biosystems Receives FDA Clearance for Aperio AT2 DX Digital Pathology System
Technology | Digital Pathology | May 29, 2019
Leica Biosystems has received clearance from the U.S. Food and Drug Administration (FDA) to market its Aperio AT2 DX...
New Blood Test Detects Colorectal Cancer Recurrence Up to 16.5 Months Earlier
News | Oncology Diagnostics | May 28, 2019
A new clinical study shows that Natera's Signatera test identified colorectal cancer recurrence up to 16.5 months...
Proton Therapy Lowers Risk of Side Effects Compared to Conventional Radiation
News | Proton Therapy | May 23, 2019
Cancer patients getting proton therapy instead of traditional photon radiation are at a significantly lower risk of...
VolparaDensity With Tyrer-Cuzick Model Improves Breast Cancer Risk Stratification
News | Breast Density | May 22, 2019
Research has demonstrated use of Volpara Solutions' VolparaDensity software in combination with the Tyrer-Cuzick Breast...